NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization34.14 mln
Float8.57 mln
Earnings Date05/15/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.01
Debt-free
ROE
-129
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Lantern Pharma is a Dallas-based drug development company focused entirely on cancer treatment, using artificial intelligence to guide its research and improve the chances of success for its drug candidates. The company is advancing several drugs through clinical trials targeting difficult-to-treat cancers, including lung cancer, pancreatic cancer, brain tumors, and certain blood cancers. Lantern also works with a number of outside partners to expand its pipeline, combining its AI-driven approach with external expertise to develop treatments for both common and rare cancer types. Founded in 2013, the company continues to build on its technology platform to make cancer drug development faster and more precise.